Atyr Pharma Inc Stock Price, News & Analysis

aTyr Pharma (NASDAQ: ATYR) has advanced ATYR0101 to IND candidate stage for treating pulmonary fibrosis. The drug candidate will be presented at the American Thoracic Society 2025 Respiratory Innovation Summit in San Francisco. ATYR0101 is a fusion protein derived from aspartyl-tRNA synthetase that targets LTBP-1 to induce myofibroblast cell death, which are key cells in fibrosis progression.

The company's preclinical data suggests ATYR0101 may have potential to reverse fibrosis, marking a significant advancement over current treatments that only slow disease progression. aTyr plans to file an IND application in the second half of 2026. This development builds on the clinical success of their lead therapy, efzofitimod, in interstitial lung disease.

aTyr Pharma (NASDAQ: ATYR) reported its Q1 2025 results and provided key updates on its clinical programs. The company's flagship Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is progressing well, with topline data expected in Q3 2025. The study enrolled 268 patients across 85 centers in nine countries. The company's Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD continues enrollment, with interim data expected in Q2 2025. Financially, aTyr reported $78.8 million in cash and investments as of March 31, 2025, with R&D expenses of $11.8 million and G&A expenses of $4.0 million for Q1. The company appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise and will present important data at the upcoming ATS 2025 International Conference.

aTyr Pharma presented promising preclinical data for their ATYR2810 antibody at the AACR Annual Meeting 2025 in Chicago. The research focuses on treating glioblastoma multiforme (GBM), an aggressive form of brain cancer.

Key findings show that ATYR2810, which targets neuropilin-2 (NRP2), demonstrated significant anti-tumor activity and improved survival rates in GBM models. The antibody proved effective both as a standalone treatment and when combined with anti-PD-1 therapies.

The research, conducted in collaboration with Stanford Medicine, revealed that ATYR2810 helps combat drug resistance by targeting immunosuppressive myeloid cells in the tumor microenvironment. The study used syngeneic tumor models, including the orthotopic CT-2A mouse model of GBM, showing enhanced anti-tumor immunity and increased overall survival.

aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, has announced its participation in two major investor conferences in April 2025. The company will attend the Jones Healthcare and Technology Innovation Conference in Las Vegas (April 8-9) and the Piper Sandler Spring Biopharma Symposium in Boston (April 17), both featuring one-on-one investor meetings.

aTyr specializes in developing first-in-class medicines using their proprietary tRNA synthetase platform. Their lead product, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The company's innovative approach involves leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation, focusing on novel domains that regulate extracellular pathways in humans.

aTyr Pharma (Nasdaq: ATYR) has announced the approval of inducement grants for three new employees by its Board's Compensation Committee on March 21, 2025. The grants consist of nonstatutory stock options to purchase 43,800 shares at a weighted-average price of $3.69 per share, matching the weighted-average closing price on Nasdaq Capital Market.

The stock options, granted under the aTyr Pharma 2022 Inducement Plan, feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4).

aTyr is developing first-in-class medicines from its tRNA synthetase platform, with its lead candidate efzofitimod targeting interstitial lung disease treatment.

aTyr Pharma (Nasdaq: ATYR) has appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Rayes brings over 25 years of experience in commercial organizations and rare disease product launches. This strategic hire comes ahead of the company's Phase 3 EFZO-FIT™ study readout for efzofitimod in pulmonary sarcoidosis, expected in Q3 2025.

Rayes previously served as Senior Vice President, Head of Commercial at ChemoCentryx, where she led the TAVNEOS® launch before Amgen's acquisition. At Actelion Pharmaceuticals, she held key commercial roles and led the VALCHLOR® rare disease franchise and OPSUMIT® launch.

As part of her appointment, Rayes received a stock option grant for 225,000 shares at $3.49 per share, vesting over four years. The company aims to potentially deliver the first new treatment for pulmonary sarcoidosis in more than 70 years.

aTyr Pharma has announced its Q4 and full year 2024 results, highlighting key developments in its clinical programs. The company completed enrollment for its global pivotal Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, with topline data expected in Q3 2025. The study, involving 268 patients across 85 centers in nine countries, received its fourth positive DSMB review.

The company's cash position stood at $75.1 million as of December 31, 2024, with an additional $18.8 million raised through ATM offering. R&D expenses were $54.4 million, while G&A expenses totaled $13.8 million for 2024. The company's cash runway is expected to extend one year beyond the Phase 3 readout, including potential BLA filing.

Additionally, enrollment continues in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related interstitial lung disease, with interim data expected in Q2 2025. A key manuscript demonstrating efzofitimod's immunomodulatory activity was published in Science Translational Medicine.

aTyr Pharma has announced a significant publication in Science Translational Medicine validating the mechanism of action of efzofitimod, their lead therapeutic candidate. The research demonstrates efzofitimod's unique anti-inflammatory mechanism targeting macrophages through the neuropilin-2 (NRP2) receptor.

The publication details how efzofitimod, derived from histidyl-tRNA synthetase (HARS), binds specifically to NRP2, which is highly expressed in inflammatory sites. This binding inhibits pro-inflammatory receptors and cytokines, potentially disrupting chronic inflammation and fibrosis cycles.

Currently, efzofitimod is undergoing a global Phase 3 EFZO-FIT™ study for pulmonary sarcoidosis and a Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD. The drug has received orphan drug designation in the U.S., E.U., and Japan for sarcoidosis, and Fast Track designation in the U.S. for both pulmonary sarcoidosis and SSc-ILD.

aTyr Pharma announced a fourth positive safety review by an independent data and safety monitoring board (DSMB) for its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis patients. The DSMB recommended continuing the study without modifications, reinforcing the therapeutic candidate's favorable safety profile.

The global Phase 3 study involves 268 subjects across multiple centers in the United States, Europe, Japan, and Brazil. The 52-week trial includes three parallel cohorts randomized to receive either 3.0 mg/kg or 5.0 mg/kg of efzofitimod or placebo, administered intravenously monthly for 12 doses. The study's primary endpoint focuses on steroid reduction, with secondary endpoints measuring lung function and sarcoidosis symptoms.

Efzofitimod is a first-in-class biologic immunomodulator targeting interstitial lung disease (ILD). The company expects to report topline results in Q3 2025.